Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7022369 | 0.98 | CCR5 (0.50) | CCR5PKMATMEPHX1RAB9A | |
| SCHEMBL18052105 | 0.96 | CCR5 (0.52) | CCR5PKMATMEPHX1RAB9A | |
| SCHEMBL7021364 | 0.96 | CCR5 (0.48) | CCR5PKMATMEPHX1RAB9A | |
| SCHEMBL18629454 | 0.88 | CCR5 (0.47) | CCR5PKMATMEPHX1RAB9A | |
| SCHEMBL7024470 | 0.85 | NPY5R (0.49) | CCR5 | |
| SCHEMBL2869853 | 0.81 | EPHX1 (0.56) | PKMEPHX1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9451038 | 0.81 | EPHX1 (0.56) | PKMEPHX1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11608613 | 0.81 | EPHX1 (0.56) | PKMATMEPHX1RAB9ANPC1 | |
| SCHEMBL135838 | 0.81 | EPHX1 (0.56) | PKMEPHX1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9547549 | 0.79 | EPHX1 (0.54) | PKMEPHX1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729628-B2 | Tyrosinase inhibitors | CONOPCO, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190117590-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM | 2019-04-25 | — | — | US | disclosed |
| EP-2367867-B1 | COMPOUNDS WITH GUANIDINE STRUCTURE AND USES THEREOF AS ORGANOPOLYSILOXANE POLYCONDENSATION CATALYSTS | BLUESTAR SILICONES FRANCE (FR) | 2018-01-03 | — | — | EP | disclosed |
| EP-1594544-B1 | ORAL COMPOSITIONS OF FENRETINIDE HAVING INCREASED BIOAVAILABILITY AND METHODS OF USING THE SAME | LOS ANGELES CHILDRENS HOSPITAL (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9050294-B2 | Treatment of neural diseases or conditions | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-06-09 | — | — | US | disclosed |
| US-9050294-B2 | Treatment of neural diseases or conditions | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-06-09 | — | — | US | disclosed |
| US-8871889-B2 | Compounds with guanidine structure and uses thereof as organopolysiloxane polycondensation catalysts | BLUESTAR SILICONES FRANCE SAS (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20140113973-A1 | TREATMENT OF NEURAL DISEASES OR CONDITIONS | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-04-24 | — | — | US | disclosed |
| US-20140113973-A1 | TREATMENT OF NEURAL DISEASES OR CONDITIONS | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-04-24 | — | — | US | disclosed |
| US-8642658-B2 | Treatment of neural diseases or conditions | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-02-04 | — | — | US | disclosed |
| CN-1031641-C | Process for preparing 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1996-04-24 | — | — | CN | disclosed |
| EP-0369744-B1 | Xanthine derivatives, process for their preparation and pharmaceutical compositions | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 1994-09-21 | — | — | EP | disclosed |
| US-5321029-A | Vascular and skin disorders; bronchodilator | BEECHAM-WUELFING GMBH & CO.K.G. (DE) | 1994-06-14 | — | — | US | disclosed |
| US-5194660-A | Processes for producing carbamates and isocyanates | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1993-03-16 | — | — | US | disclosed |
| CN-1047502-A | The preparation method of 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1990-12-05 | — | — | CN | disclosed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | disclosed |
| EP-0369744-A2 | Xanthine derivatives, process for their preparation and pharmaceutical compositions | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 1990-05-23 | — | — | EP | disclosed |
| EP-0083096-B1 | PRODUCTION OF URETHANE COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-02-25 | — | — | EP | disclosed |
| US-4621149-A | PLATINUM GROUP METAL HALOGEN OR HALOGEN COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-11-04 | — | — | US | disclosed |
| US-4240954-A | CYCLOHEXYL UREAS OR THIOUREAS | AMERICAN CYANAMID COMPANY (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117590-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | CCR5 4222/4885PKM 3045/4885ATM 4538/4885 |
| US-10729628-B2 | Tyrosinase inhibitors | TYR, MC1R, TH | CCR5 4868/4885PKM 2482/4885ATM 2933/4885 |
| US-20140113973-A1 | TREATMENT OF NEURAL DISEASES OR CONDITIONS | RARB, RARA, RARG | CCR5 3792/4885PKM 3636/4885ATM 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.